Skip to main content

URBAN HEALTH, CLIMATE AND NON-COMMUNICABLE DISEASES (NCDS)

PRE2019-089038

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Contratos Predoctorales
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Dietary circadian rhythms and cardiovascular disease risk in the prospective NutriNet-Santé cohort

  • Palomar Cros, Anna
  • Andreeva, Valentina A.
  • Fezeu, Léopold K.
  • Julia, Chantal
  • Bellicha, Alice
  • Kesse-Guyot, Emmanuelle
  • Hercberg, Serge
  • Romaguera Bosch, Dora
  • Kogevinas, Manolis
  • Touvier, Mathilde
  • Srour, Bernard
Daily eating/fasting cycles synchronise circadian peripheral clocks, involved in the regulation of the cardiovascular system. However, the associations of daily meal and fasting timing with cardiovascular disease (CVD) incidence remain unclear. We used data from 103,389 adults in the NutriNet-Santé study. Meal timing and number of eating occasions were estimated from repeated 24 h dietary records. We built multivariable Cox proportional-hazards models to examine their association with the risk of CVD, coronary heart disease and cerebrovascular disease. In this study, having a later first meal (later than 9AM compared to earlier than 8AM) and last meal of the day (later than 9PM compared to earlier than 8PM) was associated with a higher risk of cardiovascular outcomes, especially among women. Our results suggest a potential benefit of adopting earlier eating timing patterns, and coupling a longer nighttime fasting period with an early last meal, rather than breakfast skipping, in CVD prevention., The NutriNet-Santé study is supported by the following public institutions: Ministère de la Santé, Santé Publique France, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut national de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE), Conservatoire National des Arts et Métiers (CNAM) and Université Sorbonne Paris Nord. A.P.-C., D.R., and M.K. received support from the Spanish Ministry of Science and Innovation and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. A.P.-C. is supported by a MINECO (Ministry of Economy in Spain) fellowship (PRE2019-089038). Researchers were independent from funders. Funders had no role in the study design, the collection, analysis and interpretation of data, the writing of the report, and the decision to submit the article for publication.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Indoor and outdoor artificial light-at-night (ALAN) and cancer risk: a systematic review and meta-analysis of multiple cancer sites and with a critical appraisal of exposure assessment

  • Palomar Cros, Anna
  • Deprato, Andy
  • Papantoniou, Kyriaki, 1983-
  • Straif, Kurt
  • Lacy, Paige
  • Maidstone, Robert
  • Adan, Ana
  • Haldar, Prasun
  • Moitra, Saibal
  • Navarro, José Francisco
  • Durrington, Hannah
  • Moitra, Subhabrata
  • Kogevinas, Manolis
  • Harding, Barbara N.
Exposure to artificial light-at-night (ALAN) has been linked to cancer risk. Few meta-analyses on this topic have reviewed only breast cancer. This study aimed to systematically review and meta-analyze existing studies on ALAN exposure and cancer incidence, thoroughly evaluating exposure assessment quality. We considered observational studies (cohort, case-control, cross-sectional) on ALAN exposure (indoor and outdoor) and cancer incidence, measured by relative risk, hazard ratio, and odds ratio. We searched six databases, two registries, and Google Scholar from inception until April 17, 2024. Quality of studies was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. Random-effects meta-analysis was used to estimate relative risks (RR) and 95 % confidence intervals (CI) for ALAN exposures. We identified 9835 studies and included 28 for qualitative synthesis with 2,508,807 individuals (15 cohort, 13 case-control). Out of the included studies, 20 studies on breast cancer (731,493 individuals) and 2 studies on prostate cancer (53,254 individuals) were used for quantitative synthesis. Higher levels of outdoor ALAN were associated with breast cancer risk (meta-estimate = 1.12, 95 % CI 1.03-1.23 (I2 = 69 %)). We observed a non-significant positive association between indoor ALAN levels and breast cancer risk (meta-estimate = 1.07, 0.95-1.21, I2 = 60 %), and no differences by menopausal status. The meta-analysis for prostate cancer suggested a non-statistically significant increased risk for higher levels of outdoor ALAN (meta-estimate = 1.43, 0.75-2.72, I2 = 90 %). In the qualitative synthesis, we observed positive associations with non-Hodgkin lymphoma and colorectal, pancreatic and thyroid cancer. We found an association between outdoor ALAN and breast cancer risk. However, most studies relied on satellite-images with a very low resolution (1 to 5 km, from the Defense Meteorological Program [DMSP]) and without information on color of light. Future studies with better exposure assessment should focus on investigating other cancer sites., AP-C was supported by the MINECO (Ministry of Economy in Spain) Grant no. PRE2019-089038, fellowship. AD was supported by an Alberta Innovates Summer Research Studentship and a Northern Alberta Clinical Trials and Research Centre Summer Studentship Award. KP has received funding from the EU Horizon Health (Grant 101080788). PL received funding from Synergy Respiratory & Cardiac Care, Sherwood Park, AB, Canada, and AstraZeneca Canada, and she reports personal fees from AstraZeneca Canada and GSK Canada, outside the submitted work. SM reports personal fees from Elsevier Inc. (USA), Synergy Respiratory & Cardiac Care (Canada), and Permanyer Inc. (Spain); lecture fees from Apollo Gleneagles Hospital (India) and Institute of Allergy, Kolkata (India), outside the submitted work. RM and HD received funding of the Asthma and Lung UK WAPG22/100005. HD additionally received funding by MRC-CSF-MR/V029460/1. AA and JFN are supported by the grant PID2020-117767GB-I00 of Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033); AA is supported by the Generalitat de Catalunya (2021SGR801). BH has received funding from the Instituto de Salud Carlos III (ISCIII) and the European Union NextGenerationEU/PRTR (Grant IHMC22/00017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Role of circulating MicroRNAs in prostate cancer diagnosis and risk stratification in the MCC Spain study

  • Gómez-Acebo, Inés
  • Valero-Dominguez, Sara
  • Llorca, Javier
  • Alonso-Molero, Jéssica
  • Belmonte, Thalía
  • Castaño Vinyals, Gemma
  • Molina-Barceló, Ana
  • Marcos-Gragera, Rafael
  • Kogevinas, Manolis
  • Rodríguez-Cundín, Paz
  • Alguacil Ojeda, Juan
  • Pérez-Gómez, Beatriz
  • Pollán, Marina
  • Dierssen, Mara
To identify circulating microRNAs (miRNAs) associated with prostate cancer and to develop predictive models capable of distinguishing cases from controls and stratifying patients by Gleason risk categories (low, intermediate, and high risk). This case-control study included 203 prostate cancer cases and 54 population-based controls. Serum samples were analyzed by RT-qPCR (performed at QIAGEN Genomic Services). Total RNA was extracted from 200 µl of serum using the miRNeasy Serum/Plasma Advanced Kit and reverse-transcribed with the miRCURY LNA RT Kit. A panel of 46 candidate miRNAs was profiled, and feature selection was performed using LASSO penalization. Logistic regression models were used to estimate age- and covariate-adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for the association between miRNA expression and prostate cancer risk. Predictive performance was assessed using repeated 5-fold cross-validation with bootstrap resampling (10 repetitions; 1000 resamples), and summarized using the area under the receiver operating characteristic curve (AUC) with bias-corrected 95% CIs. Fourteen miRNAs were significantly associated with prostate cancer. Notably, miR-199a-5p (OR = 1.89, 95% CI: 1.13-3.15; p = 0.015) and miR-150-5p (OR = 0.20, 95% CI: 0.06-0.63; p = 0.006) showed consistent differential expression across all Gleason risk categories, with miR-199a-5p overexpressed and miR-150-5p underexpressed, suggesting a potential role in disease progression. miR-145-5p, miR-182-5p, and miR-93-5p were significantly associated with prostate cancer in both the overall model and in low- and intermediate-risk strata, highlighting their potential relevance in early-stage disease. In contrast, miR-24-3p was exclusively overexpressed in high-risk prostate cancer (OR = 2.93, 95% CI: 1.43-5.98; p = 0.003), indicating a possible link with aggressive tumor phenotypes. Predictive models demonstrated strong discriminatory performance, particularly for the low-risk group (AUC = 0.930, 95% CI: 0.882-0.979), followed by the intermediate-risk (AUC = 0.806, 95% CI: 0.728-0.883) and high-risk groups (AUC = 0.752, 95% CI: 0.658-0.848). The overall model achieved an AUC of 0.824 (95% CI: 0.756-0.892), reflecting robust performance in distinguishing cases from controls. This study identifies key circulating miRNAs associated with prostate cancer and demonstrates their potential in predictive models for risk stratification. The strongest discriminatory performance was observed in low-risk tumors (AUC = 0.930), followed by intermediate- (AUC = 0.806) and high-risk (AUC = 0.752) categories. These findings support the use of miRNAs as non-invasive biomarkers for diagnosis and personalized management of prostate cancer., This study was partially funded by the “Accion Transversal del Cancer,” approved on the Spanish Ministry Council on the 11 October 2007, Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662, PI11/01889, PI11/02213, PI12/00488, PI12/01270, PI12/00715, PI14/01219, PI14/0613, PI17/01388 and PI18/00171), Fundación Marqués de Valdecilla (API 10/09), the ICGC International Cancer Genome Consortium CLL [The ICGC CLL-Genome Project was funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)], the Junta de Castilla y León (LE22 A10-2), the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, and salud201200057018 tra), the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), the Recercaixa (2010 ACUP 00310), the Regional Government of the Basque Country, the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government—Agency for Management of University and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850, the Fundación Caja de Ahorros de Asturias, and the University of Oviedo. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. AP-C was supported by the MINECO (Ministry of Economy in Spain) Grant no. PRE2019-089038, fellowship.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Association of time of breakfast and nighttime fasting duration with breast cancer risk in the multicase-control study in Spain

  • Palomar Cros, Anna
  • Harding, Barbara N.
  • Espinosa, Ana
  • Straif, Kurt
  • Castaño Vinyals, Gemma
  • Romaguera Bosch, Dora
  • Kogevinas, Manolis
Circadian nutritional behaviors, defined by the daily eating/fasting cycle, have been linked with breast cancer. This study aimed to further disentangle the association of nighttime fasting duration and time of breakfast with breast cancer risk. We analyzed data from 1,181 breast cancer cases and 1,326 population controls from the Spanish multicase-control study (MCC-Spain), 2008-2013. We collected circadian nutritional behaviors at mid-age via a telephonic interview. We applied logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CIs) for the association of nighttime fasting duration and time of breakfast with breast cancer risk in all women and stratified by menopausal status. Models were adjusted for age, center, education, family history of breast cancer, age at menarche, number of children, breastfeeding, age at first child, body mass index (BMI), contraceptive use, and hormonal replacement therapy (HRT). A later time of breakfast was associated with a non-significant increased risk of breast cancer (OR = 1.05, 95% CI: 0.95-1.16, per hour increase). This association was stronger among premenopausal women, among whom each hour later, the time of breakfast was associated with an 18% increase in breast cancer risk (OR = 1.18, 95% CI: 1.01-1.40). The association was not observed in postmenopausal women. We did not observe an association between nighttime fasting duration and breast cancer risk after adjusting for the time of breakfast. In this study, late breakfast was associated with increased breast cancer risk, especially among premenopausal women, compared with early breakfast. Aside from nutritional quality, circadian nutritional behaviors should be further studied in relation to cancer., This study was partially funded by the “Accion Transversal del Cancer,” approved on the Spanish Ministry Council on the 11 October 2007, Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662, PI11/01889, PI11/02213, PI12/00488, PI12/01270, PI12/00715, PI14/01219, PI14/0613, and PI17/01388), Fundación Marqués de Valdecilla (API 10/09), the ICGC International Cancer Genome Consortium CLL [The ICGC CLL-Genome Project was funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)], the Junta de Castilla y León (LE22A10-2), the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, and salud201200057018tra), the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), the Recercaixa (2010ACUP 00310), the Regional Government of the Basque Country, the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government—Agency for Management of University and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850, the Fundación Caja de Ahorros de Asturias, and the University of Oviedo. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. AP-C was supported by the MINECO (Ministry of Economy in Spain) Grant no. PRE2019-089038, fellowship.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Circulating miRNAs signature on breast cancer: the MCC-Spain project

  • Gómez-Acebo, Inés
  • Llorca, Javier
  • Alonso-Molero, Jéssica
  • Díaz-Martínez, Marta
  • Pérez-Gómez, Beatriz
  • Amiano, Pilar
  • Belmonte, Thalía
  • Molina, Antonio J.
  • Burgui, Rosana
  • Castaño Vinyals, Gemma
  • Moreno, Víctor
  • Molina-Barceló, Ana
  • Marcos-Gragera, Rafael
  • Kogevinas, Manolis
  • Pollán, Marina
  • Dierssen Sotos, Trinidad
Purpose: To build models combining circulating microRNAs (miRNAs) able to identify women with breast cancer as well as different types of breast cancer, when comparing with controls without breast cancer. Method: miRNAs analysis was performed in two phases: screening phase, with a total n = 40 (10 controls and 30 BC cases) analyzed by Next Generation Sequencing, and validation phase, which included 131 controls and 269 cases. For this second phase, the miRNAs were selected combining the screening phase results and a revision of the literature. They were quantified using RT-PCR. Models were built using logistic regression with LASSO penalization. Results: The model for all cases included seven miRNAs (miR-423-3p, miR-139-5p, miR-324-5p, miR-1299, miR-101-3p, miR-186-5p and miR-29a-3p); which had an area under the ROC curve of 0.73. The model for cases diagnosed via screening only took in one miRNA (miR-101-3p); the area under the ROC curve was 0.63. The model for disease-free cases in the follow-up had five miRNAs (miR-101-3p, miR-186-5p, miR-423-3p, miR-142-3p and miR-1299) and the area under the ROC curve was 0.73. Finally, the model for cases with active disease in the follow-up contained six miRNAs (miR-101-3p, miR-423-3p, miR-139-5p, miR-1307-3p, miR-331-3p and miR-21-3p) and its area under the ROC curve was 0.82. Conclusion: We present four models involving eleven miRNAs to differentiate healthy controls from different types of BC cases. Our models scarcely overlap with those previously reported., This study was partially funded by the “Accion Transversal del Cancer,” approved on the Spanish Ministry Council on the 11 October 2007, Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662, PI11/01889, PI11/02213, PI12/00488, PI12/01270, PI12/00715, PI14/01219, PI14/0613, and PI17/01388, PI18/00171), Fundación Marqués de Valdecilla (API 10/09), the ICGC International Cancer Genome Consortium CLL [The ICGC CLL-Genome Project was funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)], the Junta de Castilla y León (LE22A10-2), the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, and salud201200057018tra), the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), the Recercaixa (2010ACUP 00310), the Regional Government of the Basque Country, the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government—Agency for Management of University and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850, the Fundación Caja de Ahorros de Asturias, and the University of Oviedo. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. AP-C was supported by the MINECO (Ministry of Economy in Spain) Grant no. PRE2019-089038, fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of circulating MicroRNAs in prostate cancer diagnosis and risk stratification in the MCC Spain study

  • Gómez-Acebo, Inés
  • Valero-Dominguez, Sara
  • Llorca, Javier
  • Alonso-Molero, Jéssica
  • Belmonte, Thalía
  • Castaño Vinyals, Gemma
  • Molina-Barceló, Ana
  • Marcos-Gragera, Rafael
  • Kogevinas, Manolis
  • Rodríguez-Cundín, Paz
  • Alguacil Ojeda, Juan
  • Pérez-Gómez, Beatriz
  • Pollán, Marina
  • Dierssen, Mara
To identify circulating microRNAs (miRNAs) associated with prostate cancer and to develop predictive models capable of distinguishing cases from controls and stratifying patients by Gleason risk categories (low, intermediate, and high risk). This case-control study included 203 prostate cancer cases and 54 population-based controls. Serum samples were analyzed by RT-qPCR (performed at QIAGEN Genomic Services). Total RNA was extracted from 200 µl of serum using the miRNeasy Serum/Plasma Advanced Kit and reverse-transcribed with the miRCURY LNA RT Kit. A panel of 46 candidate miRNAs was profiled, and feature selection was performed using LASSO penalization. Logistic regression models were used to estimate age- and covariate-adjusted odds ratios (ORs) with 95% confidence intervals (CIs) for the association between miRNA expression and prostate cancer risk. Predictive performance was assessed using repeated 5-fold cross-validation with bootstrap resampling (10 repetitions; 1000 resamples), and summarized using the area under the receiver operating characteristic curve (AUC) with bias-corrected 95% CIs. Fourteen miRNAs were significantly associated with prostate cancer. Notably, miR-199a-5p (OR = 1.89, 95% CI: 1.13-3.15; p = 0.015) and miR-150-5p (OR = 0.20, 95% CI: 0.06-0.63; p = 0.006) showed consistent differential expression across all Gleason risk categories, with miR-199a-5p overexpressed and miR-150-5p underexpressed, suggesting a potential role in disease progression. miR-145-5p, miR-182-5p, and miR-93-5p were significantly associated with prostate cancer in both the overall model and in low- and intermediate-risk strata, highlighting their potential relevance in early-stage disease. In contrast, miR-24-3p was exclusively overexpressed in high-risk prostate cancer (OR = 2.93, 95% CI: 1.43-5.98; p = 0.003), indicating a possible link with aggressive tumor phenotypes. Predictive models demonstrated strong discriminatory performance, particularly for the low-risk group (AUC = 0.930, 95% CI: 0.882-0.979), followed by the intermediate-risk (AUC = 0.806, 95% CI: 0.728-0.883) and high-risk groups (AUC = 0.752, 95% CI: 0.658-0.848). The overall model achieved an AUC of 0.824 (95% CI: 0.756-0.892), reflecting robust performance in distinguishing cases from controls. This study identifies key circulating miRNAs associated with prostate cancer and demonstrates their potential in predictive models for risk stratification. The strongest discriminatory performance was observed in low-risk tumors (AUC = 0.930), followed by intermediate- (AUC = 0.806) and high-risk (AUC = 0.752) categories. These findings support the use of miRNAs as non-invasive biomarkers for diagnosis and personalized management of prostate cancer., This study was partially funded by the “Accion Transversal del Cancer,” approved on the Spanish Ministry Council on the 11 October 2007, Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662, PI11/01889, PI11/02213, PI12/00488, PI12/01270, PI12/00715, PI14/01219, PI14/0613, PI17/01388 and PI18/00171), Fundación Marqués de Valdecilla (API 10/09), the ICGC International Cancer Genome Consortium CLL [The ICGC CLL-Genome Project was funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)], the Junta de Castilla y León (LE22 A10-2), the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, and salud201200057018 tra), the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), the Recercaixa (2010 ACUP 00310), the Regional Government of the Basque Country, the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government—Agency for Management of University and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850, the Fundación Caja de Ahorros de Asturias, and the University of Oviedo. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. AP-C was supported by the MINECO (Ministry of Economy in Spain) Grant no. PRE2019-089038, fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Indoor and outdoor artificial light-at-night (ALAN) and cancer risk: a systematic review and meta-analysis of multiple cancer sites and with a critical appraisal of exposure assessment

  • Palomar Cros, Anna
  • Deprato, Andy
  • Papantoniou, Kyriaki, 1983-
  • Straif, Kurt
  • Lacy, Paige
  • Maidstone, Robert
  • Adan, Ana
  • Haldar, Prasun
  • Moitra, Saibal
  • Navarro, José Francisco
  • Durrington, Hannah
  • Moitra, Subhabrata
  • Kogevinas, Manolis
  • Harding, Barbara N.
Exposure to artificial light-at-night (ALAN) has been linked to cancer risk. Few meta-analyses on this topic have reviewed only breast cancer. This study aimed to systematically review and meta-analyze existing studies on ALAN exposure and cancer incidence, thoroughly evaluating exposure assessment quality. We considered observational studies (cohort, case-control, cross-sectional) on ALAN exposure (indoor and outdoor) and cancer incidence, measured by relative risk, hazard ratio, and odds ratio. We searched six databases, two registries, and Google Scholar from inception until April 17, 2024. Quality of studies was assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. Random-effects meta-analysis was used to estimate relative risks (RR) and 95 % confidence intervals (CI) for ALAN exposures. We identified 9835 studies and included 28 for qualitative synthesis with 2,508,807 individuals (15 cohort, 13 case-control). Out of the included studies, 20 studies on breast cancer (731,493 individuals) and 2 studies on prostate cancer (53,254 individuals) were used for quantitative synthesis. Higher levels of outdoor ALAN were associated with breast cancer risk (meta-estimate = 1.12, 95 % CI 1.03-1.23 (I2 = 69 %)). We observed a non-significant positive association between indoor ALAN levels and breast cancer risk (meta-estimate = 1.07, 0.95-1.21, I2 = 60 %), and no differences by menopausal status. The meta-analysis for prostate cancer suggested a non-statistically significant increased risk for higher levels of outdoor ALAN (meta-estimate = 1.43, 0.75-2.72, I2 = 90 %). In the qualitative synthesis, we observed positive associations with non-Hodgkin lymphoma and colorectal, pancreatic and thyroid cancer. We found an association between outdoor ALAN and breast cancer risk. However, most studies relied on satellite-images with a very low resolution (1 to 5 km, from the Defense Meteorological Program [DMSP]) and without information on color of light. Future studies with better exposure assessment should focus on investigating other cancer sites., AP-C was supported by the MINECO (Ministry of Economy in Spain) Grant no. PRE2019-089038, fellowship. AD was supported by an Alberta Innovates Summer Research Studentship and a Northern Alberta Clinical Trials and Research Centre Summer Studentship Award. KP has received funding from the EU Horizon Health (Grant 101080788). PL received funding from Synergy Respiratory & Cardiac Care, Sherwood Park, AB, Canada, and AstraZeneca Canada, and she reports personal fees from AstraZeneca Canada and GSK Canada, outside the submitted work. SM reports personal fees from Elsevier Inc. (USA), Synergy Respiratory & Cardiac Care (Canada), and Permanyer Inc. (Spain); lecture fees from Apollo Gleneagles Hospital (India) and Institute of Allergy, Kolkata (India), outside the submitted work. RM and HD received funding of the Asthma and Lung UK WAPG22/100005. HD additionally received funding by MRC-CSF-MR/V029460/1. AA and JFN are supported by the grant PID2020-117767GB-I00 of Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033); AA is supported by the Generalitat de Catalunya (2021SGR801). BH has received funding from the Instituto de Salud Carlos III (ISCIII) and the European Union NextGenerationEU/PRTR (Grant IHMC22/00017). ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association of time of breakfast and nighttime fasting duration with breast cancer risk in the multicase-control study in Spain

  • Palomar Cros, Anna
  • Harding, Barbara N.
  • Espinosa, Ana
  • Straif, Kurt
  • Castaño Vinyals, Gemma
  • Romaguera Bosch, Dora
  • Kogevinas, Manolis
Circadian nutritional behaviors, defined by the daily eating/fasting cycle, have been linked with breast cancer. This study aimed to further disentangle the association of nighttime fasting duration and time of breakfast with breast cancer risk. We analyzed data from 1,181 breast cancer cases and 1,326 population controls from the Spanish multicase-control study (MCC-Spain), 2008-2013. We collected circadian nutritional behaviors at mid-age via a telephonic interview. We applied logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CIs) for the association of nighttime fasting duration and time of breakfast with breast cancer risk in all women and stratified by menopausal status. Models were adjusted for age, center, education, family history of breast cancer, age at menarche, number of children, breastfeeding, age at first child, body mass index (BMI), contraceptive use, and hormonal replacement therapy (HRT). A later time of breakfast was associated with a non-significant increased risk of breast cancer (OR = 1.05, 95% CI: 0.95-1.16, per hour increase). This association was stronger among premenopausal women, among whom each hour later, the time of breakfast was associated with an 18% increase in breast cancer risk (OR = 1.18, 95% CI: 1.01-1.40). The association was not observed in postmenopausal women. We did not observe an association between nighttime fasting duration and breast cancer risk after adjusting for the time of breakfast. In this study, late breakfast was associated with increased breast cancer risk, especially among premenopausal women, compared with early breakfast. Aside from nutritional quality, circadian nutritional behaviors should be further studied in relation to cancer., This study was partially funded by the “Accion Transversal del Cancer,” approved on the Spanish Ministry Council on the 11 October 2007, Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662, PI11/01889, PI11/02213, PI12/00488, PI12/01270, PI12/00715, PI14/01219, PI14/0613, and PI17/01388), Fundación Marqués de Valdecilla (API 10/09), the ICGC International Cancer Genome Consortium CLL [The ICGC CLL-Genome Project was funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)], the Junta de Castilla y León (LE22A10-2), the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, and salud201200057018tra), the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), the Recercaixa (2010ACUP 00310), the Regional Government of the Basque Country, the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government—Agency for Management of University and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850, the Fundación Caja de Ahorros de Asturias, and the University of Oviedo. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. AP-C was supported by the MINECO (Ministry of Economy in Spain) Grant no. PRE2019-089038, fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Circulating miRNAs signature on breast cancer: the MCC-Spain project

  • Gómez-Acebo, Inés
  • Llorca, Javier
  • Alonso-Molero, Jéssica
  • Díaz-Martínez, Marta
  • Pérez-Gómez, Beatriz
  • Amiano, Pilar
  • Belmonte, Thalía
  • Molina, Antonio J.
  • Burgui, Rosana
  • Castaño Vinyals, Gemma
  • Moreno, Víctor
  • Molina-Barceló, Ana
  • Marcos-Gragera, Rafael
  • Kogevinas, Manolis
  • Pollán, Marina
  • Dierssen Sotos, Trinidad
Purpose: To build models combining circulating microRNAs (miRNAs) able to identify women with breast cancer as well as different types of breast cancer, when comparing with controls without breast cancer. Method: miRNAs analysis was performed in two phases: screening phase, with a total n = 40 (10 controls and 30 BC cases) analyzed by Next Generation Sequencing, and validation phase, which included 131 controls and 269 cases. For this second phase, the miRNAs were selected combining the screening phase results and a revision of the literature. They were quantified using RT-PCR. Models were built using logistic regression with LASSO penalization. Results: The model for all cases included seven miRNAs (miR-423-3p, miR-139-5p, miR-324-5p, miR-1299, miR-101-3p, miR-186-5p and miR-29a-3p); which had an area under the ROC curve of 0.73. The model for cases diagnosed via screening only took in one miRNA (miR-101-3p); the area under the ROC curve was 0.63. The model for disease-free cases in the follow-up had five miRNAs (miR-101-3p, miR-186-5p, miR-423-3p, miR-142-3p and miR-1299) and the area under the ROC curve was 0.73. Finally, the model for cases with active disease in the follow-up contained six miRNAs (miR-101-3p, miR-423-3p, miR-139-5p, miR-1307-3p, miR-331-3p and miR-21-3p) and its area under the ROC curve was 0.82. Conclusion: We present four models involving eleven miRNAs to differentiate healthy controls from different types of BC cases. Our models scarcely overlap with those previously reported., This study was partially funded by the “Accion Transversal del Cancer,” approved on the Spanish Ministry Council on the 11 October 2007, Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533, PI08/1359, PS09/00773, PS09/01286, PS09/01903, PS09/02078, PS09/01662, PI11/01889, PI11/02213, PI12/00488, PI12/01270, PI12/00715, PI14/01219, PI14/0613, and PI17/01388, PI18/00171), Fundación Marqués de Valdecilla (API 10/09), the ICGC International Cancer Genome Consortium CLL [The ICGC CLL-Genome Project was funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)], the Junta de Castilla y León (LE22A10-2), the Consejería de Salud of the Junta de Andalucía (PI-0571-2009, PI-0306-2011, and salud201200057018tra), the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10), the Recercaixa (2010ACUP 00310), the Regional Government of the Basque Country, the Consejería de Sanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, the Spanish Association Against Cancer (AECC) Scientific Foundation, by the Catalan Government—Agency for Management of University and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850, the Fundación Caja de Ahorros de Asturias, and the University of Oviedo. ISGlobal acknowledges support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S) and support from the Generalitat de Catalunya through the CERCA Program. AP-C was supported by the MINECO (Ministry of Economy in Spain) Grant no. PRE2019-089038, fellowship.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Dietary circadian rhythms and cardiovascular disease risk in the prospective NutriNet-Santé cohort

  • Palomar Cros, Anna
  • Andreeva, Valentina A.
  • Fezeu, Léopold K.
  • Julia, Chantal
  • Bellicha, Alice
  • Kesse-Guyot, Emmanuelle
  • Hercberg, Serge
  • Romaguera Bosch, Dora
  • Kogevinas, Manolis
  • Touvier, Mathilde
  • Srour, Bernard
Daily eating/fasting cycles synchronise circadian peripheral clocks, involved in the regulation of the cardiovascular system. However, the associations of daily meal and fasting timing with cardiovascular disease (CVD) incidence remain unclear. We used data from 103,389 adults in the NutriNet-Santé study. Meal timing and number of eating occasions were estimated from repeated 24 h dietary records. We built multivariable Cox proportional-hazards models to examine their association with the risk of CVD, coronary heart disease and cerebrovascular disease. In this study, having a later first meal (later than 9AM compared to earlier than 8AM) and last meal of the day (later than 9PM compared to earlier than 8PM) was associated with a higher risk of cardiovascular outcomes, especially among women. Our results suggest a potential benefit of adopting earlier eating timing patterns, and coupling a longer nighttime fasting period with an early last meal, rather than breakfast skipping, in CVD prevention., The NutriNet-Santé study is supported by the following public institutions: Ministère de la Santé, Santé Publique France, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut national de recherche pour l’agriculture, l’alimentation et l’environnement (INRAE), Conservatoire National des Arts et Métiers (CNAM) and Université Sorbonne Paris Nord. A.P.-C., D.R., and M.K. received support from the Spanish Ministry of Science and Innovation and State Research Agency through the “Centro de Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. A.P.-C. is supported by a MINECO (Ministry of Economy in Spain) fellowship (PRE2019-089038). Researchers were independent from funders. Funders had no role in the study design, the collection, analysis and interpretation of data, the writing of the report, and the decision to submit the article for publication.